Agenus Inc. (AGEN)’s Financial Results Comparing With Dynavax Technologies Corporation (NASDAQ:DVAX)

Agenus Inc. (NASDAQ:AGEN) and Dynavax Technologies Corporation (NASDAQ:DVAX) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus Inc. 38.69M 12.30 147.18M -1.40 0.00
Dynavax Technologies Corporation 2.90M 229.07 146.35M -2.36 0.00

Table 1 demonstrates Agenus Inc. and Dynavax Technologies Corporation’s gross revenue, earnings per share and valuation.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Agenus Inc. -380.41% 136.2% -110.7%
Dynavax Technologies Corporation -5,046.55% -98.6% -57.7%

Volatility and Risk

Agenus Inc. has a beta of 2.27 and its 127.00% more volatile than Standard and Poor’s 500. Dynavax Technologies Corporation’s 53.00% less volatile than Standard and Poor’s 500 volatility due to the stock’s 0.47 beta.


Agenus Inc.’s Current Ratio and Quick Ratio are 1.2 and 1.2 respectively. The Current Ratio and Quick Ratio of its competitor Dynavax Technologies Corporation are 6.3 and 5.9 respectively. Dynavax Technologies Corporation therefore has a better chance of paying off short and long-term obligations compared to Agenus Inc.

Analyst Ratings

The Recommendations and Ratings for Agenus Inc. and Dynavax Technologies Corporation are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agenus Inc. 0 0 0 0.00
Dynavax Technologies Corporation 0 0 1 3.00

Competitively Dynavax Technologies Corporation has a consensus target price of $25, with potential upside of 135.85%.

Insider & Institutional Ownership

Roughly 32.4% of Agenus Inc. shares are owned by institutional investors while 77.7% of Dynavax Technologies Corporation are owned by institutional investors. Agenus Inc.’s share owned by insiders are 0.1%. Competitively, insiders own roughly 0.7% of Dynavax Technologies Corporation’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agenus Inc. 9.13% 27.05% 32.83% -9.62% -27.35% -19.33%
Dynavax Technologies Corporation -3.81% -9.94% -14.07% -31.2% -38.41% -41.87%

For the past year Agenus Inc. was less bearish than Dynavax Technologies Corporation.


Agenus Inc. beats on 6 of the 11 factors Dynavax Technologies Corporation.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodyÂ’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The companyÂ’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.